eagle about to land

Has the eagle landed? Find out in our July issue

  • Nathan I. Cherny
Perspective

Announcements

  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic

  • group of five women

    Happy International Women's Day 2022! #BreakTheBias To mark International Women's Day, the Nature Reviews journals present a Collection of articles featuring in-depth content on the biology and health conditions in people with female-specific organs and hormonal cycles.

Advertisement

    • Liquid biopsy assays of diverse cancer-associated molecular alterations in blood, including genomic, epigenomic, transcriptomic, proteomic and metabolomics changes, offer considerable opportunities for early detection of cancer as well as improved management of the disease. In this Perspective, the authors review key advances in liquid biopsy-based multi-omics approaches for biomarker discovery. They also introduce the ‘nano-omics’ paradigm, whereby nanotechnology tools are used to capture and enrich various cancer-derived analytes from biofluids for subsequent omics analyses, with the aim of developing novel biomarker panels for early cancer detection.

      • Lois Gardner
      • Kostas Kostarelos
      • Marilena Hadjidemetriou
      Perspective
    • Radiotheranostics enables the clinician to image and then target lesions using the same probe. Despite this appealing potential, interest in the field of radiotheranostics has long been constrained by a lack of expertise, high infrastructure costs and the availability of non-radioactive alternative approaches. Nonetheless, several recent successes have led to renewed research interest. In this Review, the authors summarize the current challenges and opportunities in this rapidly emerging area.

      • Lisa Bodei
      • Ken Herrmann
      • Jason S. Lewis
      Review Article
    • A recent study not only confirms mounting evidence that technology-facilitated symptom monitoring improves care and should be considered for all patients with cancer, but also suggests that patient navigators can help to deliver such interventions. Herein we discuss how such an approach can minimize disparities and maximize access to culturally appropriate patient-centred care.

      • Gabrielle B. Rocque
      • Abby R. Rosenberg
      News & Views
    • Neuroblastomas are tumours of sympathetic origins typically seen in infants (≤5 years of age). In this Review, the authors describe progress in the treatment of patients with neuroblastoma, which has resulted in considerable improvements in survival outcomes over the past several decades. The authors then summarize ongoing attempts to personalize therapy in patients with high-risk disease, and to safely de-escalate therapy in those with low-risk disease.

      • Bo Qiu
      • Katherine K. Matthay
      Review Article
    • Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial.

      • Boris Sepesi
      • Stephen G. Swisher
      News & Views

Nature Careers

Events

Jobs

Advertisement